T

    Tenaya Therapeutics Inc (TNYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.69
    -0.00 (-0.33%)

    Market Cap: $154.74M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(14/21)
    Avg Surprise
    -0.50%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.10
    Range$-0.10 - $-0.09
    5 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$-0.10-2.7%
    60d ago$-0.10-2.7%
    30d ago$-0.10-2.7%
    7d ago$-0.10-2.7%
    Current$-0.10
    Revenue Consensus
    $802500
    Range$0 - $1M
    4 analysts
    Dec 31, 2026
    EPS Consensus$-0.21
    Range$-0.24 - $-0.15
    3 analysts
    Revenue Consensus
    $-14302500
    Range$-17002500 - $-8072500
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.21---
    Sep 26EST
    		-$-0.10---
    Jun 26
    		$-0.09$-0.08-12.50%Miss+35.7%
    Mar 26
    		$-0.09$-0.09+0.00%Beat+62.5%
    Dec 25
    		$-0.12$-0.14+12.73%Beat+57.1%
    Sep 25
    		$-0.12$-0.15+20.00%Beat+60.0%
    Jun 25
    		$-0.14$-0.19+26.32%Beat+58.8%
    Mar 25
    		$-0.24$-0.20-20.00%Miss+40.0%
    Dec 24
    		$-0.28$-0.31+9.68%Beat+30.0%
    Sep 24
    		$-0.30$-0.37+18.92%Beat+23.1%
    Jun 24
    		$-0.34$-0.39+12.82%Beat+24.4%
    Mar 24
    		$-0.40$-0.42+4.76%Beat+7.0%
    Dec 23
    		$-0.40$-0.44+9.09%Beat+34.4%
    Sep 23
    		$-0.39$-0.48+18.75%Beat+47.3%
    Jun 23
    		$-0.45$-0.51+11.76%Beat+34.8%
    Mar 23
    		$-0.43$-0.55+21.82%Beat+42.7%
    Dec 22
    		$-0.61$-0.65+6.15%Beat+3.2%
    Sep 22
    		$-0.74$-0.68-8.82%Miss-8.8%
    Jun 22
    		$-0.69$-0.74+6.76%Beat+94.8%
    Mar 22
    		$-0.75$-0.64-17.19%Miss-87.5%
    Dec 21
    		$-0.63$-0.60-5.00%Miss+94.7%
    Sep 21
    		$-0.68$-0.48-41.67%Miss+93.3%
    Jun 21
    		$-13.26$-7.17-84.94%Miss-
    Mar 21
    		$-0.40$0.00N/AMiss-
    Dec 20
    		$-11.93$0.00N/AMiss-
    Dec 19
    		$-10.15$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.64EV/EBITDA-0.67x
    Price/FCF-2.85xFCF Yield-35.14%
    Profitability
    Profit Margin0.00%Operating Margin-1883.00%
    ROE-121.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.52xQuick Ratio4.52x
    Trading Statistics
    Beta2.79Avg Volume2.06M
    52-Week High$2.3552-Week Low$0.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.69
    SMA 20$0.72
    SMA 50$0.76
    SMA 200$0.81
    EMA 10$0.70
    EMA 20$0.71
    EMA 50$0.74
    EMA 200$0.82

    MACD

    Line: -0.02Signal: -0.02Hist: -0.00

    ADX

    ADX: 11.9+DI: 14.4-DI: 21.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down80.0
    PSAR$0.75

    Bollinger Bands

    Upper Band$0.77
    Lower Band$0.66
    %B Position1606%(Upper)
    Band Width0.25

    RSI (14-Day)

    Neutral
    40.5

    Momentum Oscillators

    Stoch %K25.9
    Stoch %D28.0
    Williams %R-76.5
    ROC (10d)-1.8%
    Momentum-0.01
    CCI (20d)-88.9
    MFI (14d)29.8

    Volatility Measures

    ATR (14d)$0.04(5.5%)
    StdDev (20d)0.03
    Hist Vol48.0%(High)

    Volume Flow

    VWAP$0.69
    OBV-5.2M
    AD Line-101.2M
    CMF (20d)-0.310

    Volume Metrics

    Avg Vol (20d)2.1M
    Vol Ratio0.7x
    VWMA (20d)$0.72

    Pivot Points

    R3$0.72
    R2$0.71
    R1$0.70
    Pivot Point$0.69
    S1$0.68
    S2$0.68
    S3$0.67

    Advanced Oscillators

    TSI-17.50
    Ultimate Osc38.7
    KST-101.60

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.11M$225,000$0$0$0$0$0$0$0$0$17.66M$0
    Cost of Revenue$0$0$-3,948,000$0$0$0N/A$0$0$0$2.99M$0
    Gross Profit$1.11M$225,000$3.95M$0$0$0N/A$0$0$0$-2,987,000$0
    Operating Expenses$45.20M$20.29M$24.72M$20.94M$24.08M$27.54M$24.65M$26.71M$30.82M$33.76M$31.45M$30.92M
    R&D$16.60M$14.84M$14.80M$15.36M$17.37M$21.08M$18.69M$20.35M$22.65M$25.05M$22.86M$23.09M
    SG&A$5.41M$5.45M$5.98M$5.57M$6.71M$6.46M$5.96M$6.36M$8.17M$8.71M$8.58M$7.83M
    Operating Income$-44,088,000$-20,065,000$-20,775,000$-20,936,000$-24,082,000$-27,538,000$-24,652,000$-26,711,000$-30,823,000$-33,762,000$-31,446,000$-30,920,000
    Interest Income$697,000$793,000$575,000$658,000$815,000$635,000$812,000$1.08M$1.39M$1.45M$1.47M$1.78M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-43,393,000$-19,272,000$-20,175,000$-20,275,000$-23,283,000$-26,864,000$-23,836,000$-25,634,000$-29,431,000$-32,228,000$-29,935,000$-29,143,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-43,393,000$-19,272,000$-20,175,000$-20,275,000$-23,283,000$-26,864,000$-23,836,000$-25,634,000$-29,431,000$-32,228,000$-29,935,000$-29,143,000
    EBITDA$-42,392,000$-18,302,000$-18,348,000$-18,958,000$-21,745,000$-24,807,000$-22,799,000$-24,625,000$-28,559,000$-31,599,000$-27,538,000$-29,053,000
    EBIT$-44,090,000$-20,065,000$-20,175,000$-20,933,000$-24,098,000$-27,499,000$-24,648,000$-26,714,000$-30,824,000$-33,680,000$-31,405,000$-30,919,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TNYA

    News

    Israel Englander group takes passive stake in Tenaya Therapeutics (TNYA)

    A group led by Israel Englander, including Integrated Core Strategies (US) LLC, Millennium Management LLC, and Millennium Group Management LLC, has reported a 5.2% passive stake in Tenaya Therapeutics (TNYA) via a Schedule 13G SEC filing. Integrated Core Strategies (US) LLC beneficially owns 11,579,445 shares, while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 11,581,565 shares. The filing indicates shared voting and dispositive power for these entities and emphasizes that the stake is for investment purposes, not for changing control of the issuer.

    Stock Titan•8/24/26•
    Neutral

    Tenaya therapeutics CEO Ali Faraz sells $15.8k in company shares

    Tenaya Therapeutics CEO Ali Faraz sold $15,777 worth of company shares to cover tax obligations related to vesting restricted stock units. This transaction involved 22,232 shares at prices between $0.6820 and $0.7253. Despite a 44% decline in TNYA shares over the past year, the stock has recently gained 11%, although it remains highly volatile.

    Investing.com•8/18/26•
    Neutral

    Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

    Tenaya Therapeutics (NASDAQ: TNYA) is set to provide key updates in the fourth quarter on its cardiac gene therapy programs, TN-201 and TN-401, as well as its small-molecule candidate TN-301. The company is developing precision medicines for heart disease, focusing on addressing underlying causes. Tenaya expects to fund operations through the third quarter of next year with its current $78 million in cash, not including potential pivotal or Phase 2 trial costs.

    MarketBeat•8/18/26•
    Bullish

    Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock

    Tenaya Therapeutics' CMO, Tingley Whittemore, sold 7,424 shares of common stock for $5,267 on August 17, 2026, primarily to cover tax withholding from restricted stock unit vestings. The sales occurred as TNYA shares trade near $0.70, significantly down over the past year, despite an InvestingPro analysis suggesting it trades below its fair value. The company also recently reported interim clinical trial data and appointed a new CFO.

    Investing.com•8/18/26•
    Somewhat-Bearish

    Tenaya Therapeutics (NASDAQ:TNYA) CEO Sells $15,784.72 in Stock

    Tenaya Therapeutics CEO Faraz Ali sold 22,232 shares worth $15,784.72 to cover tax withholding obligations, reducing his direct holdings by 5.05%. The sale occurred on August 17th, with shares trading at $0.71. This insider transaction comes as Tenaya Therapeutics faces a stock decline, disappointing earnings, and mixed analyst ratings, though institutional investors maintain a significant stake.

    MarketBeat•8/18/26•
    Somewhat-Bearish

    Frequently Asked Questions About TNYA

    Does TNYA pay dividends?
    Tenaya Therapeutics Inc (TNYA) does not currently pay a regular dividend.
    What is TNYA's market cap?
    Tenaya Therapeutics Inc (TNYA) has a market capitalization of $154.74M with a current stock price of $0.69.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In